What is Eccogene?
Eccogene is a clinical-stage biopharmaceutical company dedicated to pioneering best-in-class small molecule therapeutics. Their primary focus is on developing innovative oral therapies designed to combat chronic cardiometabolic and inflammatory diseases. The company's strategic approach involves creating treatments that can complement existing therapies, such as GLP-1 receptor agonists, by addressing a broader spectrum of patient needs beyond weight management. Eccogene's pipeline features promising clinical programs targeting THR-β and SSAO, alongside preclinical initiatives aimed at metabolic diseases. This commitment to advancing medical care aims to enhance treatment options for millions globally.
How much funding has Eccogene raised?
Eccogene has raised a total of $25M across 1 funding round:
Series B
$25M
Series B (2023): $25M with participation from Zhangjiang Healthcare Venture Capital, Huajin Capital, New Alliance Capital, and Oriza Seed Capital
Key Investors in Eccogene
Zhangjiang Healthcare Venture Capital
Zhangjiang Healthcare Venture Capital is an investor focused on the healthcare sector, likely backing companies with innovative therapeutic approaches.
Huajin Capital
Huajin Capital is an investment firm that likely provides strategic financial backing to companies within its portfolio.
New Alliance Capital
New Alliance Capital is a venture capital firm based in Shanghai, China, specializing in investments within the technology and innovation sectors.
What's next for Eccogene?
With this substantial enterprise-level funding, Eccogene is strategically positioned to accelerate the development and potential commercialization of its innovative drug candidates. The capital infusion is expected to fuel the progression of its clinical trials and expand its research and development capabilities. The company's focus on addressing unmet needs in cardiometabolic and inflammatory diseases, coupled with its pipeline diversification, suggests a trajectory aimed at capturing significant market share and improving patient outcomes worldwide. Future growth will likely involve further clinical validation and strategic partnerships to bring these advanced therapies to market.
See full Eccogene company page
